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ABSTRACT
Objective: The aim of this study was to evaluate the efficacy of mitoxantrone versus daunorubicin
on the response rates of acute myeloid leukemia (AML) patients.
Methodology: In this prospective randomized trial, adult patients with newly diagnosed AML
received daunorubicin(45mg/m²/d for 3 days) or mitoxantrone (12mg/m²/d for 3 days), each
combined with the identical dose of cytarabine(ara-c) (150mg/m²/d by continuous infusion for 7
days). Of 27 patients, 10 were randomly allocated to the mitoxantrone plus ara-c “MA”
treatment arm and 17 to the daunorubicin plus ara-c “DA” treatment arm.
Results: Median age of the patients in MA was18 years and in DA was 25. Fifty percent of the MA
achieved complete remission and 40% achieved a partial remission giving an overall response
rate of %90. The same overall response rate was significantly lower in DA group (P=0.025).
Conclusion: The combination of mitoxantrone and ara-c is a possible alternative to daunorubicin
and ara-c combination for the treatment of AML.
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INTRODUCTION
A combination of anthracycline and
cytarabine has been used as the standard in-
duction therapy of AML since 1973. A routine,
classic and standard induction regimen (7 and
3 regimen) is now available with cytarabine
(100mg/m2 daily) by continuous infusion on
days one through seven and daunorubicin
(45mg/m² daily) on days one through day
three. A complete remission (CR) rate of 55-90
percent has been reported.1 Most studies of in-
duction therapy of AML have showed that
advanced age is the most negatively influenc-
ing factor affecting the achievement of CR.2
Mitoxantrone is an anthraquinone that has
replaced anthracyclines in some cytarabine-
containing induction regimens. Early studies
suggested that mitoxantrone might be better
tolerated causing less alopecia, gastrointestinal
toxicity, and possibly, less cardiac toxicity com-
pared to anthracyclines.3-5 It has been used
more often at relapse and in the elderly.3,5-7
The aim of this study was to evaluate the
efficacy of mitoxantrone versus daunorubicin
on the response rates of AML patients.
PATIENTS AND METHODS
In this prospective randomized trial, adult
patients with newly diagnosed AML received
910   Pak J Med Sci   2007   Vol. 23   No. 6      www.pjms.com.pk
Alireza Nikanfar et al.
daunorubicin or mitoxantrone, each combined
with the identical dose of cytarabine.
Eligibility: Adult patients under the age of 60
with a morphologically confirmed diagnosis of
previously untreated AML by French-Ameri-
can-British (FAB) criteria were eligible. Most
of the patients had flowcytometric
immunophenotype confirmation of the diag-
nosis, but cytogenetic study was not available.
Patients with secondary AML were excluded.
They should have had a performance status of
0-2 defined by World Health Organization.
Required initial laboratory data included crea-
tinine and serum bilirubin levels less than 1.5
time the upper limits of the normal.
A normal left ventricular ejection fraction
assessed with echocardiography was required.
Subjects with cardiovascular disease including
recent (less than 6 months) myocardial infarc-
tion and those with any active bacterial, viral
and fungal infections were excluded.
Study Design: Patients were randomly assigned
to one of two remission induction treatment
arms:
1. (MA) cytarabine 150mg/m2 daily for 24
hour continuous intravenous infusion on
days one through day seven and
mitoxantrone 12mg/m2 intravenous daily
on days one through day three.
2. (DA) cytarabine as the same as (MA)  arm
plus daunorubicin 45mg/m2 intravenous
daily on days one through day three.
A bone marrow aspirate was obtained on day
14. If the marrow showed five percent or more
blasts, a second cycle of induction chemo-
therapy was administered. The dose of drugs
administered for cycle two was the same as
cycle one. Response to remission induction
therapy was evaluated according to the crite-
ria defined in a workshop sponsored by the
National Cancer Institute.3 CR was defined as
the normalization of neutrophil counts (at least
1.5 ×109/L) and platelet counts (>100× 109/L)
and a marrow aspirate and biopsy showing at
least 20% cellularity, less than five percent
blasts and no Auer rods as well as absence of
extramedullary leukemia. Partial remission
defined by 5 to 25 percent blasts.
Statistical Methods: Descriptive statistics using
SPSS11 soft ware were calculated to document
the response rates. Two proportions Z-test was
used to compare response rates between two
groups of subjects received MA and DA treat-
ment protocols. P-values = 0.05 or less was
considered significant.
RESULTS
A total of 29 patients were recruited for this
study. Two patients, one from each treatment
arm, were excluded because of early death. Of
27 remaining subjects, 10 were randomly
allocated to the MA treatment arm and 17 to
the DA treatment arm. Patients and disease
characteristics of the subjects is presented in
Table-I. Two groups of patients were almost
similar. The study sample comprised seven
males and three females in MA group with
median (range) age of 18 (13-43). The same
figures were four males and 13 females with
median (range) of 25 (14-52) in DA group.
Table-II shows the response rates to induc-
tion therapy of subjects by treatment. As seen
in the table, five (50 percent) of the MA group
Table-I: Basic characteristics of the subjects
MA DA
(n=10) (n=17)  
Sex
  Male (no.) 7 4
  Female (no.) 3 13
Age (years)
  Median (range) 18 (13-43) 25 (14-52)
  40 and less (no.) 9 16
  41-59 (no.) 1 1
  60 and more (no.) 0 0
FAB type
  M1 (no.) 1 1
  M2 (no.) 5 8
  M3 (no.) 2 4
  M4 (no.) 2 4
  Hb (gr/dl)
  Median (range) 8.6 (5.2-11.3) 7.4 (5.2-10.4)
Plt (count × 109/l)
  Median (range) 58.5 (19-210) 32 (10-101)
WBC (count × 109/l)
  Median (range) 8.5 (0.47-95.5) 23.5 (1.8-370)
  0-49 (no.) 7 10
  50-99 (no.) 3 3
  100+ (no.) 0 4
Abbreviation: Hb ,hemoglobin. Plt, platelet.
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achieved CR and four (40 percent) achieved a
PR giving an overall response rate (CR+PR) of
90 percent. The same overall response rate was
significantly lower in DA group (P=0.025).
Responses to induction chemotherapy by se-
lected clinical and disease characteristics are
shown in (Table-III). There was no statistical
significant difference between two groups in
terms of any of gender, age, FAB types and
white blood cell (WBC) count.
DISCUSSION
Mitoxantrone is a synthetic anthraquinone
that has been used for several years in the treat-
ment of AML. Its use has been based on its in-
complete cross-resistance with other interca-
lating agents, and its better tolerance.8 In com-
bination with cytarabine, mitoxantrone has
been found to be effective in the treatment of
refractory and relapsed AML.9 The present
study was designed to compare the efficacy of
this less toxic and well tolerated drug to
daunorubicin as induction therapy in the
newly diagnosed adult patients with AML
under the age of 60. Higher CR rate with MA
versus DA regimen (50% compared to 35%) in
this study was not significant (P=0.45), but
overall response rate (CR+PR) in MA group
was significantly brtter than DA group
(P=0.025). The limitation of trial was the small
number of cases and the absence of cytogenetic
study.
Mitoxantrone has been used more often in
the elderly.5,10,11 In one study a regimen of
mitoxantrone(10mg/m² for 4 days) and
cytarabine (100 mg/m² twice daily for 5
days)was evaluated as first line therapy in eld-
erly patients (>60 years) with AML. Of 86 cases
with de-novo AML, 64% achieved CR and 6%
achieved PR giving an overall response rate of
70%.5
Another group treated 33 older patients (>59
years)with newly diagnosed AML ,with
mitoxantrone (12mg/m²/d for 3 days or 10
mg/m²/d for 5 days) and cytarabine (100mg/
m² twice daily for 7 days) and observed 48%
CR rates.10 In another study, in AML in the
elderly, cytarabine was administered at a dose
of 100mg/m² for 7 days and combined with
either mitoxantrone 8mg/m² or daunomycine
30mg/m² daily for 3 days. A significantly
higher CR (P=0.069) was observed with
mitoxantrone (47% compared with 38%).11
Limited trials reported high CR with
mitoxantrone and cytarabime in newly diag-
nosed AML patients without direct compari-
son with daunorubicin.12-14 In another research
29 patients with newly diagnosed AMLwere
treated with mitoxantrone and cytarabine in
the same dose as in the present study and 83%
CR rate was reported.12
In one study in Kuwait 21 patients with pre-
viously untreated AML were treated, with se-
quential mitoxantrone and standard dose
cytararbine and 80% CR rate was observed.13
In yet another study in Turkey a trial was
conducted to evaluate the impact of mode of
administration of mitoxantrone in combination
with standard dose cytarabine on the response
rates in 40 newly diagnosed patients with
Table-II: Response to induction therapy
of subjects by treatment
MA DA
(n=10) (n=17)
CR no.(%) 5 (50) 6 (35)
PR no.(%) 4 (40) 2 (12)
NR no.(%) 1 (10) 9 (53)
Response Rate (%) 90 47
P-value = 0.025
Table-III: CR rate (%) in MA and DA treatments
  MA   DA P-Value
(n=10) (n=17)
Sex
  Male 57 25 0.3
  Female 33 38.5 0.87
Age (years)
  40 and less 55 37.5 0.38
  41-59 0 0  - -
  60 and more - - - -  - -
FAB type
  M1 100 0 0.15
  M2 60 25 0.21
  M3 50 50  - -
  M4 0 50 0.22
WBC (count ×109/l)
  0-99 50 46.2 0.85
  100+ - - 0  - -
All patients 50 35 0.45
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AML and observed 75% and 80% CR rates in
the bolus and continuous infusion arms,
respectively.14
In a study of similar design to the present
study, authors compared DA with MA regi-
men in the same dose and schedule as in the
present study. Because there were no signifi-
cant differences between MA and DA regimen
with respect to CR rate (63% compared to
53%), survival or toxicity, the investigators con-
cluded that MA and DA were comparable in
the first line treatment of patients with AML.
However, in that study patients treated with
MA were more likely to achieve CR with one
induction course than were patients treated
with DA.15 In another study with similar
design , investigators demonstrated similar
incidence of CR with MA and DA
regimen(53%compared with 43%).16 Higher
CR rate with MA versus DA in this study is
similar to that reported in other trials.
We conclude that the combination of
mitoxantrone and cytarabine is a possible
alternative to daunorubicin and cytarabine
combination for the treatment of AML.
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